CD1 and MR1 Recognition by Human γδ T Cells
Overview
Molecular Biology
Authors
Affiliations
The two main T cell lineages, αβ and γδ T cells, play a central role in immunity. Unlike αβ T cells that recognize antigens bound to the Major Histocompatibility Complex (MHC) or MHC class I-like antigen-presenting molecules, the ligands for γδ T cell receptors (TCRs) are much more diverse. However, it is now clear that γδ TCRs can also recognize MHC class I-like molecules, including CD1b, CD1c, CD1d and the MHC class I-related protein 1 (MR1). Yet, our understanding at the molecular level of γδ T cell immunity to CD1 and MR1 is still very limited. Here, we discuss new molecular paradigms underpinning γδ TCRs recognition of antigens, antigen-presenting molecules or both. The recent discovery of recognition of MR1 by a γδ TCR at a position located underneath the antigen display platform reinforces the view that γδ TCRs can approach their ligands from many directions, unlike αβ TCRs that bind MHC, CD1 and MR1 targets in an aligned, end to end fashion.
Recognition of MR1-antigen complexes by TCR Vγ9Vδ2.
Loureiro J, Vacchini A, Berloffa G, Devan J, Schaefer V, Nosi V Front Immunol. 2025; 16:1519128.
PMID: 40040716 PMC: 11876030. DOI: 10.3389/fimmu.2025.1519128.
Research Progress of γδT Cells in Tumor Immunotherapy.
Li Y, Mo X, Yao H, Xiong Q Cancer Control. 2024; 31:10732748241284863.
PMID: 39348473 PMC: 11459529. DOI: 10.1177/10732748241284863.
Current annotation strategies for T cell phenotyping of single-cell RNA-seq data.
Mullan K, de Vrij N, Valkiers S, Meysman P Front Immunol. 2024; 14:1306169.
PMID: 38187377 PMC: 10768068. DOI: 10.3389/fimmu.2023.1306169.
Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies.
Meringa A, Hernandez-Lopez P, Cleven A, de Witte M, Straetemans T, Kuball J Front Immunol. 2023; 14:1159337.
PMID: 37441064 PMC: 10333927. DOI: 10.3389/fimmu.2023.1159337.